Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study

Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study

Early treatment with antivirals against SARS-CoV-2 infection can prevent the onset of severe COVID-19 in fragile and immunocompromised patients. In this real-life, prospective, observational study, we evaluated efficacy and safety of a 3-day early treatment with remdesivir in adult and fragile patie...

Full description

Bibliographic Details
Main Authors: Riccardo Scotto, Antonio Riccardo Buonomo, Antonio Iuliano, Maria Foggia, Alessia Sardanelli, Riccardo Villari, Biagio Pinchera, Ivan Gentile, Federico II COVID-Team
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Vaccines
Subjects:
COVID-19
SARS-CoV-2
remdesivir
monoclonal antibodies
hospitalization
fragile
Online Access:https://www.mdpi.com/2076-393X/11/2/200

Internet

https://www.mdpi.com/2076-393X/11/2/200

Similar Items